While it is still early days, the microbiome space is heating up with a number of biotech start-ups appearing on the scene over the past 12 months. Cambridge, Mass.-based Seres Therapeutics Inc. is hoping to capitalize on that rising tide of investor interest by filing its S-1 registration statement with the SEC to raise up to $100 million in an IPO.